Literature DB >> 23793312

Transcription activity of MMP-2 and MMP-9 metalloproteinase genes and their tissue inhibitor (TIMP-2) in acute coronary syndrome patients.

J Dabek1, J Glogowska-Ligus, B Szadorska.   

Abstract

BACKGROUND: Acute coronary syndromes (ACS) are a consequence of coronary vessel atherosclerosis and they are a leading cause of death in industrialized countries. One of the ACS causative factors is the deranged ratio equilibrium of the matrix metalloproteinase/tissue inhibitor of metalloproteinases (MMPs/TIMPs). AIMS: Assessment of transcriptional activity of metalloproteinase genes using Human Genome-U133A oligonucleotide microarrays and selection of candidate genes differentiating ACS patients from healthy subjects and finally, QRT-PCR (quantitative real time polymerase chain reaction) confirmation of the results. SETTINGS AND
DESIGN: The study involved 67 ACS patients, admitted on a consecutive basis, to the Cardiology Clinic as well as 24 healthy subjects (control).
MATERIALS AND METHODS: Ribonucleic acid isolated from peripheral blood mononuclear cells was analyzed by QRT-PCR. Transcriptional activity of the analyzed gene was assessed with TaqMan gene expression assays. STATISTICAL ANALYSIS: U Mann-Whitney test was used to compare the results.
RESULTS: Homogeneity of the investigated group was assessed through hierarchical clusterization whereas the nine genes differentiating ACS patients from healthy persons were selected using the Bland-Altman technique. Among these genes three (platelet derived growth factor D, NUAK family SNF1-like kinase 1 and peroxisomal biogenesis factor 1) showed decreased transcriptional activity whereas the remaining six genes (MMP-2 and MMP-9, CDK5RAP3, transmembrane BAX inhibitor motif containing 1, adenylate cyclase-associated protein 1 and TIMP-2) were increased. MMP-2, MMP-9 and TIMP-2 were further characterized by QRT-PCR.
CONCLUSIONS: The obtained results permit to conclude that the increased expression of MMP-2 and MMP-9 metalloproteinases and their tissue inhibitor (TIMP-2) is responsible for disturbed equilibrium of the metalloproteinase/tissue inhibitors system and as a consequence, for destabilization of atherosclerotic plaque and occurrence of the acute coronary syndrome in the investigated group of patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23793312     DOI: 10.4103/0022-3859.113836

Source DB:  PubMed          Journal:  J Postgrad Med        ISSN: 0022-3859            Impact factor:   1.476


  5 in total

1.  Impact of losartan and angiotensin II on the expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rat vascular smooth muscle cells.

Authors:  Yan-Song Guo; Zong-Gui Wu; Jun-Ke Yang; Xin-Jing Chen
Journal:  Mol Med Rep       Date:  2014-11-14       Impact factor: 2.952

2.  Patients with chronic three-vessel disease in a 15-year follow-up study: genetic and non-genetic predictors of survival.

Authors:  Jan Máchal; Monika Pávková-Goldbergová; Ota Hlinomaz; Ladislav Groch; Anna Vašků
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

3.  Rapamycin inhibits CaCl2-induced thoracic aortic aneurysm formation in rats through mTOR-mediated suppression of proinflammatory mediators.

Authors:  Jiumei Cao; Qihong Wu; Liang Geng; Xiaonan Chen; Weifeng Shen; Fang Wu; Ying Chen
Journal:  Mol Med Rep       Date:  2017-06-22       Impact factor: 2.952

4.  Doxycycline Decreases Atherosclerotic Lesions in the Aorta of ApoE-⁄- and Ovariectomized Mice with Correlation to Reduced MMP-2 Activity.

Authors:  Keuri E Rodrigues; Aline Azevedo; Pricila R Gonçalves; Maria H B Pontes; Gustavo M Alves; Ruan R Oliveira; Cristine B Amarante; João P M Issa; Raquel F Gerlach; Alejandro F Prado
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

Review 5.  Matrix Metalloproteinases as Biomarkers of Atherosclerotic Plaque Instability.

Authors:  Wioletta Olejarz; Dominika Łacheta; Grażyna Kubiak-Tomaszewska
Journal:  Int J Mol Sci       Date:  2020-05-31       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.